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The core phenotype of anorexia nervosa (AN) comprises the age and stage dependent
intertwining of both its primary and secondary (i.e., starvation induced) somatic
and mental symptoms. Hypoleptinemia acts as a key trigger for the adaptation to
starvation by affecting diverse brain regions including the reward system and by
induction of alterations of the hypothalamus-pituitary-“target-organ” axes, e.g., resulting
in amenorrhea as a characteristic symptom of AN. Particularly, the rat model activity-
based anorexia (ABA) convincingly demonstrates the pivotal role of hypoleptinemia in
the development of starvation-induced hyperactivity. STAT3 signaling in dopaminergic
neurons in the ventral tegmental area (VTA) plays a crucial role in the transmission of
the leptin signal in ABA. In patients with AN, an inverted U-shaped relationship has
been observed between their serum leptin levels and physical activity. Albeit obese
and therewith of a very different phenotype, humans diagnosed with rare congenital
leptin deficiency have starvation like symptoms including hypothalamic amenorrhea in
females. Over the past 20 years, such patients have been successfully treated with
recombinant human (rh) leptin (metreleptin) within a compassionate use program. The
extreme hunger of these patients subsides within hours upon initiation of treatment;
substantial weight loss and menarche in females ensue after medium term treatment. In
contrast, metreleptin had little effect in patients with multifactorial obesity. Small clinical
trials have been conducted for hypothalamic amenorrhea and to increase bone mineral
density, in which metreleptin proved beneficial. Up to now, metreleptin has not yet been
used to treat patients with AN. Metreleptin has been approved by the FDA under strict
regulations solely for the treatment of generalized lipodystrophy. The recent approval by
the EMA may offer, for the first time, the possibility to treat extremely hyperactive patients
with AN off-label. Furthermore, a potential dissection of hypoleptinemia-induced AN
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symptoms from the primary cognitions and behaviors of these patients could ensue.
Accordingly, the aim of this article is to review the current state of the art of leptin
in relation to AN to provide the theoretical basis for the initiation of clinical trials for
treatment of this eating disorder.
Keywords: anorexia, leptin, hyperactivity, metreleptin treatment, starvation, physical activity
INTRODUCTION
Improvements in the treatment of patients with AN have been
made over the past decades. In particular, patients have profited
from an increased awareness of the disorder both among the lay
public and health care professionals leading to earlier treatment
and a change in the perception of the disorder (Hebebrand
et al., 2004; Hebebrand and Bulik, 2011; American Psychiatric
Association [APA], 2013). Importantly, the DSM-IV A criterion
(American Psychiatric Association [APA], 2000) “refusal to
maintain body weight at or above a minimally normal weight
for age and height” was replaced with “restriction of energy
intake relative to requirements” in DSM-5, thus correcting the
long-standing notion of an actively and willfully pursued reduced
food intake (see Hebebrand and Bulik, 2011). As such, more rigid
treatment regimens including for instance extended periods of
bed rest and therapeutic cutback or even prohibition of exercise
have given way to a more fluid approach toward these patients
acknowledging the fact that as yet unknown mechanisms prevent
the maintenance of a healthy body weight. The shift in the
perception of this eating disorder was undoubtedly supported
by the discovery of the complex pathways underlying body
weight regulation and the insight that, for example, only a
low percentage of individuals with obesity can successfully
maintain a reduced body weight over time (Friedman,
2004; Wing and Phelan, 2005; Bray and Wadden, 2015;
MacLean et al., 2015; Soleymani et al., 2016).
Despite these improvements, AN remains a debilitating
disorder that substantially perturbs somatic and psychological
maturation during the important developmental stages of
adolescence and early adulthood. In those two-thirds of
patients in whom recovery eventually occurs, the mean
duration of AN and subsequent eating disorders amounted
to 7.5 (±4.7) years according to a Swedish study (Wentz
et al., 2001). Furthermore, recovery in itself is relative
because former patients may continue to have residual
Abbreviations: ABA, activity-based anorexia; AgRP, agouti-related protein; AN,
anorexia nervosa; BMI, body mass index; DAT KO, dopamine-transporter
knockout; DNA, deoxyribonucleic acid; DSM-5, Diagnostic and Statistical Manual
of Mental Disorders, 5th Edition; EMA, European Medicines Agency; FDA, Food
and Drug Administration; FOXO1, Forkhead box protein O1; FSH, follicle-
stimulating hormone; HPA, hypothalamo-pituitary axis; ICD-11, International
Classification of Diseases – 11; ICV, intracerebroventricular; IRS, insulin receptor
substrate; JAK, Janus kinase; KATP, ATP-sensitive potassium channel; LEPR, leptin
receptor; LH, luteinizing hormone; LRb, long form of leptin receptor; PI3K,
phosphatidylinositide 3-kinase; POMC, proopiomelanocortin; PTB1B, protein
tyrosine phosphatase 1B; RCT, randomized controlled trial; r-metHuLeptin,
recombinant methionyl human leptin; RWA, running wheel activity; SH2,
Src-homology 2; SHP2, Src homology phosphatase 2; SIH, starvation-induced
hyperactivity; SOCS3, suppressor of cytokine signaling 3; STAT3, signal-
transducer activator transcription 3; TRP, tyrosinase-related protein; VTA, ventral
tegmental area.
eating disorder-related cognitions and behaviors at the
subclinical level (Espindola and Blay, 2013). Noteworthy,
AN is the mental disorder with the highest standardized
mortality rate (Sullivan, 1995; Arcelus et al., 2011). Accordingly,
both psychotherapeutic and pharmacological treatments
of AN still leave substantial room for improvement
(Hebebrand et al., 2019, in press).
Whereas today body weight fear and body image disturbances
are viewed as essential diagnostic criteria for AN (DSM-5),
we need to appreciate that the combination of underweight
and amenorrhea was common in times prior to the coining of
the term AN by Gull (1997). Thus, chlorosis was a disorder
of females that persisted in different forms from the 16th
century to approximately 1920; descriptions of chlorosis refer
to amenorrhea and a “capricious or depraved appetite,” which
included “anorexia, or at least a reduced food intake, sometimes
associated with nausea and vomiting” and pica (Loudon, 1980).
The phenomenon of the transient occurrence of fasting saints in
the middle ages (Vandereycken and Van Deth, 2001), too, raises
the question of a many centuries old core pathology that includes
underweight to the degree of starvation.
Our longstanding interest in leptin and AN began with the
first study to demonstrate that serum concentrations in patients
with AN are reduced (Hebebrand et al., 1995) published one year
after the discovery of leptin (Zhang et al., 1994). We later for
the first time showed that treatment of food restricted rats with
leptin prevents the development of semi-SIH in a rat model for
AN (Exner et al., 2000) similar to the model ABA (Routtenberg
and Kuznesof, 1967). In this combined selective review and
medical hypothesis article, we focus on the possibility to reduce
starvation-induced symptoms in patients with AN by treatment
with metreleptin (a human recombinant leptin analog).
We initially provide the reader with a synopsis of the function
of leptin and the development of metreleptin, its success in
treatment of patients with congenital leptin deficiency, and its
approval for the treatment of generalized lipodystrophy, which
as in AN is metabolically characterized by hypoleptinemia.
We continue by distinguishing between potential somatic and
psychological/behavioral benefits that we would expect after
initiation of metreleptin treatment of patients with AN based
on the alterations incurred during starvation. Because two
controlled trials (Welt et al., 2004; Sienkiewicz et al., 2011)
have already been conducted in patients with hypothalamic
amenorrhea – albeit without a current diagnosis of an eating
disorder – we cursorily review these studies. We extend our
previous major focus on the potential to treat the hyperactivity
of patients (Hebebrand and Albayrak, 2012) in light of
the aforementioned rodent data. Due to the relevance of
the reward system for both AN and leptin, we selectively
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summarize the current research status. We argue for the
potential of metreleptin to curtail the reward inherent to
both the characteristic dieting behavior and hyperactivity of
these patients, and thus, facilitation of weight restoration. We
additionally explore the possibility that application of metreleptin
at an early stage of AN may prevent the progression to
an addictive like disease state. We conclude by delineating
target symptoms for future clinical studies and by pointing
out potential adverse events that may result from metreleptin
treatment. In light of the dire need to increase treatment
options for patients with AN, we hope that our admittedly
selective compilation of research findings will nevertheless
help to initiate clinical trials examining effects of metreleptin
treatment in AN.
LEPTIN: FUNCTION, REGULATION, AND
RECOMBINANT LEPTIN
Leptin is involved in numerous biological functions, which apart
from weight regulation include innate and adaptive immunity,
reproduction, and bone formation (Peelman et al., 2014). The
hormone leptin is comprised of 167 amino acids (Halaas et al.,
1995; Auwerx and Staels, 1998), which in its non-glycosylated
mature form is reduced to 146 amino acids (Peelman et al.,
2014). As an adipokine, it is expressed mainly in adipocytes
(Kawakami et al., 1999). Upon secretion into the blood stream,
leptin is largely bound to the short form of the LEPR, which lacks
the transmembrane domain (Chan et al., 2002); its circulating
concentration is influenced by gender, adiposity, sex hormones,
and recombinant human (rh) leptin administration (Chan et al.,
2002). In lean persons with 21% or less body fat, 60–98%
of total leptin was bound whereas in obese individuals, more
than 50% of the total leptin concentration circulates in the
free form (Sinha et al., 1996). Circulating plasma leptin levels
increase in proportion to body fat stores (Fried et al., 2000).
Expression is elevated by feeding [about 4–7 h postprandial
(Fried et al., 2000), increased insulin (Wabitsch et al., 1996;
Marques-Oliveira et al., 2018), and glucocorticoids (Wabitsch
et al., 1996; Fried et al., 2000)]. Androgens contribute to gender
differences in leptin production and inhibit leptin expression in
human adipocytes (Wabitsch et al., 1997). Leptin concentrations
dropped by approximately 75% in females who underwent a 60 h
fast (Bergendahl et al., 1999). Leptin is predominantly actively
transported across the blood–brain barrier by means of a complex
saturable transport system (Banks et al., 1996; Pan and Kastin,
2007; Kastin and Pan, 2016) including the soluble form of the
LEPR (Kastin and Pan, 2000, 2008). Only a small proportion of
leptin reaches the brain by passive diffusion (Diaz et al., 2006).
Leptin can finally reach all regions of the brain, not only the
hypothalamus (Banks et al., 2000).
Six LEPR isoforms have been identified. As delineated above,
the short form of the LEPR is relevant for the systemic
availablity of the hormone (Peelman et al., 2014). Only the LRb
encompassing 1162 residues including an intracellular domain
of 302 amino acids is presumed to be capable of JAK/signal-
transducer activator of transcription 3 (STAT3) signaling. This
isoform is highly expressed in the specific nuclei of the
hypothalamus relevant for body weight regulation, in other brain
regions (Mercer et al., 1996), and in many peripheral tissues
including, for instance, the reproduction system (ovaries, uterus),
lung, bone, blood, tongue, and hair follicles (Hoggard et al., 1997;
Iguchi et al., 2001; Bjorbaek and Kahn, 2004). The extent to
which central or peripheral binding of leptin is relevant for its
specific functions is still a matter of research (Margetic et al.,
2002; Peelman et al., 2014). The functions of the other isoforms
have not yet been clarified; they are assumed to play a role
in the transport across the blood–brain barrier and in renal
clearance of leptin.
Activation of the LRb (Tartaglia et al., 1995), a type I cytokine
receptor encoded by LEPR (Tartaglia et al., 1995), initiates the
JAK – (STAT3) pathway (Fernandes et al., 2015) (see Figure 1).
After binding to hypothalamic neurons, autophosphorylation
of JAK2 and subsequent recruitment and phosphorylation of
STAT3 take place. Phosphorylated STAT3 thereafter dimerizes;
the dimer is able to enter the nucleus, where it binds to
specific DNA elements in the POMC or AgRP promoter
regions in the hypothalamus causing POMC activation (Ernst
et al., 2009) and AgRP repression (Varela and Horvath, 2012).
Subsequent to activation of the STAT3 pathway, leptin induces
SOCS3 (suppression of cytokine signaling 3), which functions
as a feedback inhibitor of leptin signaling (Bjorbaek et al.,
1999). Leptin sensitivity within this signaling cascade is further
controlled by (a) PTP1B, which dephosphorylates STAT3, thus,
reducing leptin sensitivity of expression of POMC (Banno et al.,
2010) and (b) the SH2 domain-containing protein tyrosine
phosphatase-2 (SHP2), which also dephosphorylates STAT3 at
different positions (Banno et al., 2010) to maintain leptin
sensitivity. SHP2 is thought to integrate leptin and estrogen
signals in females (He et al., 2012). Last but not least, SOCS3
inhibits the actions of SHP2 to repress the phosphorylated
pSTAT3 pathway adding to the complex orchestrated interplay
in leptin signaling pathways (St-Pierre and Tremblay, 2012).
In a neuron specific manner, leptin is also capable to activate
the PI3K pathway thereby leading to (a) a depolarization
of POMC neurons via downstream non-specific cation TRP
channel activation and (b) hyperpolarization of AgRP neurons
by PI3K-mediated opening of KATP channels resulting in a
potassium outflow (Gavello et al., 2016). In contrast to leptin,
insulin hyperpolarizes both POMC and AgRP neurons by PI3K-
mediated activation of KATP channels (Qiu et al., 2014; Huang
and Xiao, 2018). Downstream of PI3K, insulin and leptin both
stimulate the phosphorylation and nuclear exclusion of Forkhead
protein (FOXO1), thus suppressing AgRP transcription and
enabling POMC transcription (Kitamura et al., 2006). The
increments of POMC and after its cleavage of α-, ß-, and γ-
MSH increase the inhibitory tone in the melanocortin system and
result in reduced appetite (Raab et al., 2003; Horvath et al., 2010;
Hinney et al., 2013, 2014; Lucas et al., 2015).
There is clear evidence that leptin is involved – in concert
with insulin – in midbrain reward circuits (Fulton et al., 2000;
Davis et al., 2010; Hebebrand et al., 2014; Coccurello and
Maccarrone, 2018). Thus, receptors for insulin and leptin are
expressed on dopaminergic (DA) neurons in the VTA/substantia
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FIGURE 1 | Leptin metabolism pathway. IRS: insulin receptor substrate; JAK: Janus kinase; KATP: ATP-sensitive potassium channel; FOXO1: Forkhead box protein
O1; PI3K: phosphatidylinositide 3-kinase; PTB1B: protein tyrosine phosphatase 1B; SHP2: Src homology phosphatase 2; SOCS3: suppressor of cytokine signaling
3; STAT3: signal-transducer activator transcription 3; TRP: transient receptor potential.
nigra (Hommel et al., 2006) as shown immunohistochemically
(Figlewicz et al., 2003), hence substantiating that these metabolic
hormones have the capacity to reach the respective brain areas
(Banks et al., 2000) and alter reward behaviors and motivational
drives for food intake (Figlewicz, 2016). LEPR binding neurons
are, however, absent in the amygdala and striatum, but the central
amygdala receives extensive projections from LEPR binding DA
neurons originating in the VTA (Leshan et al., 2010). Animal
models revealed that at five stimulation sites near the fornix,
food restriction enhanced the effectiveness of rewarding electrical
stimulation; the rewarding effect was attenuated by ICV infusion
of leptin (Fulton et al., 2000). Interestingly, the stimulation of
some neighboring sites was insensitive to food restriction but
enhanced by central leptin administration pointing toward a
not yet fully understood Janus effect of leptin regarding the
reward system (Fulton et al., 2000). Leptin signaling in the VTA
is also involved in the regulation of anxiety-related behaviors
(Liu et al., 2011, 2015).
History of the Development of
Metreleptin and Its Use as a Drug
In 1995, Amgen Inc. (Thousand Oaks, CA, United States)
bought the commercial rights on metreleptin from Rockefeller
University and involved scientists (Fliesler, 2009). At that time,
hopes were erroneously high that metreleptin would prove
successful for treatment of multifactorial obesity (Rosenbaum
et al., 2008) and obese patients with type II diabetes (Moon et al.,
2011). In 2006, the rights were sold to Amylin Pharmaceuticals
(subsidiary of Bristol-Myers Squibb since 2012), where leptin
was tested in combination with its diabetes drug pramlintide
(Fliesler, 2009; Chou and Perry, 2013; FDA, 2014). However,
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despite favorable weight-loss data (Ravussin et al., 2009), Amylin
Pharmaceuticals discontinued further development due to
“commercial considerations” (FDA, 2014). AstraZeneca, through
its partnership with Bristol-Myers Squibb, acquired the global
rights for metreleptin in February 2014 and sold it to Aegerion
in January 2015 (AstraZeneca, 2014).
Metreleptin with the brand name Myalept R© was first approved
in 2014 by the FDA and indicated to treat the complications
of leptin deficiency in patients with congenital or acquired
generalized lipodystrophy after submission of a biologics license
application by Amylin Pharmaceuticals (FDA, 2014; Meehan
et al., 2016). In July 2018, the European Medical Agency (EMA,
2018) also granted marketing authorization to Aegerion for
Myalapta R© for treatment of lipodystrophy (confirmed congenital
generalized or acquired generalized, or familial or acquired
partial lipodystrophy) (orphan decision number: EU/3/12/1022;
EMA, 2018).
The human hormone leptin is instable in vivo (Roujeau et al.,
2014) with a short plasma half-life of mean 24.9± 4.4 min (Klein
et al., 1996). Metreleptin (r-Met-hu-leptin) is a non-glycosylated
16 kDa recombinant analog with one additional methionine
residue at the amino terminus (half-life of 3.8–4.7 h) developed
by Amgen for subcutaneous administration (McLennan et al.,
2003) and tested in clinical trials for obesity (Heymsfield
et al., 1999). After five trials, results were disillusioning. Obese
individuals presented with high circulating leptin levels; an
elevation of these levels failed to induce adequate weight loss
during recombinant leptin therapy (FDA, 2014), thus supporting
the concept of “leptin resistance.”
Metreleptin represents a mechanistically based targeted
therapy for individuals with rare mutations of the leptin gene
entailing inborn functional leptin deficiency (Farooqi et al., 1999).
It is one of very few causal treatments currently available for
monogenic types of obesity (Farooqi et al., 1999; Farooqi and
O’Rahilly, 2014; Kuhnen et al., 2016; Muller et al., 2016; Collet
et al., 2017; Clement et al., 2018). Aside from an immediate
reduction of appetite/hunger and subsequent medium-term
substantial weight loss, the treatment with recombinant leptin
entails also positive effects on fertility, cognition, and mental
health-related aspects (Paz-Filho et al., 2008) presumably
triggered by intra- and extra-hypothalamic effects of leptin in
the brain (Paz-Filho et al., 2011; Farooqi and O’Rahilly, 2014).
Similar to the ob/ob mouse (Chehab et al., 1996), human inborn
leptin deficiency results in hypogonadotropic hypogonadism
with an impact on the maturation of the reproductive system in
affected girls. Treatment with (r-metHuLeptin) leads to a rapid
induction of gonadotropin secretion and menarche in pubertal
and post-pubertal females (Montague et al., 1997; Farooqi et al.,
1999; Bluher et al., 2009; von Schnurbein et al., 2012).
ADAPTATION TO STARVATION AND THE
KEY ROLE OF HYPOLEPTINEMIA AS
THE MAJOR ENDOCRINE TRIGGER
A prolonged negative energy balance (i.e., reduced energy
intake relative to energy expenditure) leads to starvation and
triggers complex neural, metabolic, hormonal, and behavioral
adaptations to promote survival. The maintenance of energy
supply for the brain and the protection of lean mass are
crucial within this adaptation process (Ahima and Flier, 2000a).
Carbohydrate metabolism is switched to fat-based metabolism
via a fall in insulin and rise in counter-regulatory hormones, i.e.,
glucagon, epinephrine, and glucocorticoids. A decrease in thyroid
and gonadal hormones, increased adrenal glucocorticoids,
decreased body temperature, and increased appetite represent
further adaptive processes, whose net effect is to stimulate
gluconeogenesis to provide glucose for vital cellular function
and supply fatty acids for use by skeletal muscle. Importantly,
energy utilization is minimized during fasting via suppression
of thyroid thermogenesis and curtailment of procreation and
growth (Ahima and Flier, 2000b).
Keys et al. (1963) extensively studied the somatic and
psychological effects of starvation (see Table 1) in the Minnesota
Starvation Experiment, during which young male adults were
food restricted (mean energy intake of ∼1600 kcal/day taking
TABLE 1 | Starvation in humans: somatic and mental/behavioral symptoms
(Michaels, 2013; Gale Encyclopedia of Medicine, 2019).
Somatic symptoms Mental/behavioral symptoms
Shrinkage of organs and
gradual loss of their functions:
Hunger, craving, pre-occupation with
food
Gastrointestinal tract
Heart
Lungs
Liver
Kidneys
Ovaries or testes
Chronic diarrhea Abnormal eating behavior
Eating smallest amounts
Eating extremely slowly
Ritualized eating behavior
Anemia Depressed mood
Reduction in muscle mass and
consequent weakness
Anxiety
Lowered body temperature
combined with extreme
sensitivity to cold
Irritability
Decreased ability to digest food
because of lack of digestive
acid production
Inflexible thinking
Immune deficiency Limited spontaneity
Swelling from fluid under the
skin
Restrained initiative
Delayed puberty Restrained emotional expression
Amenorrhea Social withdrawal
Bradycardia and arrhythmia Loss of ambition
Hypoglycemia and abnormal
glucose tolerance
Rigidity
Protein deficiency Reduced cognitive ability and memory
Osteoporosis Impaired concentration
Dry and discolored skin, lanugo
hair
Decreased sex drive
Frontiers in Psychology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 769
fpsyg-10-00769 May 16, 2019 Time: 14:39 # 6
Hebebrand et al. Treatment of Patients With Anorexia Nervosa
individual metabolic needs into account) over a period of 6
months, until they reached a body weight corresponding to
approximately 75% of baseline weight. The effects of starvation
have also been analyzed in areas of famine and include studies
on prenatal and intergenerational as well as long-term somatic
and mental effects (e.g., Dutch famine; Susser and Stein,
1994; Susser et al., 1998; Painter et al., 2005). Because of the
associated nutrient deficiencies, these results are not directly
transferable to AN. Most patients with AN do not initially
develop profound nutrient deficiencies (Van Binsbergen et al.,
1988) because of comparatively high nutrient-density of their
energy restricted diet.
Despite the obvious importance of starvation in the phenotype
of AN (Hebebrand and Bulik, 2011) DSM-5 merely provides
recommendations for the definition of a “significantly low body
weight in the context of age, sex, developmental trajectory, and
physical health” including the use of a BMI cut-off of 18.5 kg/m2
in adults and the fifth BMI age centile in children and adolescents
with AN. The DSM-5 reference to physical health seemingly
suggests that somatic symptoms of starvation should have set in
to endorse the weight criterion and at the same time negates the
fact that mental health is also affected by starvation.
Leptin acts as one, if not the key endocrine trigger, of
the adaptation processes required to enhance the likelihood
of survival during starvation (Ahima and Flier, 2000b). As
fat mass decreases during a period of a negative energy
balance, circulating leptin levels drop below critical thresholds,
thus, initiating cascades affecting the step by step adaptation
to starvation. In parallel to the reduced secretion of leptin
upon food restriction both the hypothalamic (Giovambattista
et al., 2000) and peripheral LEPRs are upregulated (Cohen
et al., 2005), indicating an elevated sensitivity to the hormone
during starvation.
Patients with AN present hypoleptinemia in accordance with
both their reduced energy intake and fat mass (Hebebrand et al.,
1995, 1997, 2007; Grinspoon et al., 1996). Consistent with results
obtained in normal weight and overweight individuals, serum
leptin levels in patients with AN show a higher correlation to
body fat than to BMI (Grinspoon et al., 1996; Mathiak et al.,
1999). The serum levels are below those of age, BMI, and
sex matched controls including constitutionally thin females
(Hebebrand et al., 1997; Eckert et al., 1998; Kopp et al., 1998;
Germain et al., 2007; Föcker et al., 2011). A serum leptin
level of approximately 2 µg/L predicts both AN and a lifetime
history of secondary amenorrhea in underweight females and
also largely separates patients with AN from those with bulimia
nervosa (Kopp et al., 1998; Föcker et al., 2011), indicating
that serum leptin can be used to screen for AN or serve
as a diagnostic marker (Hebebrand and Bulik, 2011). Weight
restoration expectedly entails an increase in leptin secretion,
which after several weeks can intermittently exceed that of BMI
and sex matched healthy controls (Figure 2).
Similar to individuals with inborn functional leptin deficiency,
the reduced function of the reproductive axis and amenorrhea
in AN has been linked to the hypoleptinemia of patients with
AN (Hebebrand et al., 2003, 2007; Hebebrand and Albayrak,
2012). Mean serum log10 leptin levels over the first 4 weeks of
inpatient treatment were correlated with mean FSH, LH, and
estradiol levels, respectively (Kopp et al., 1997, 1998). Upon
weight restoration, the rise in leptin secretion precedes that of LH
and FSH (Ballauff et al., 1999; Wabitsch et al., 2001).
PROVEN EFFICACY OF RECOMBINANT
LEPTIN FOR TREATMENT OF
HYPOTHALAMIC AMENORRHEA AND
BONE LOSS AND ITS POTENTIAL FOR
STARVATION-RELATED REDUCED
BLOOD CELL PRODUCTION
The fact that the application of recombinant leptin in eight
patients over a 3-month period led to menstruation and/or
growth of follicles in excessively exercising and/or low weight
females who presented with hypothalamic amenorrhea of at least
a half year duration, can be viewed as proof of the crucial role
of leptin in reproductive function (Welt et al., 2004); within the
small scaled RCT improvements of reproductive function were
not observed in the six controls. Metreleptin treatment increased
mean LH levels and LH pulse frequency after 2 weeks and
increased maximal follicular diameter, the number of dominant
follicles, ovarian volume, and estradiol levels during the 3-month
long treatment period. Three and two of the eight patients
had an ovulatory menstrual cycle or a pre-ovulatory follicular
development and withdrawal bleeding during treatment. Levels
of free triiodothyronine, free thyroxine, insulin-like growth factor
1, insulin-like growth factor-binding protein 3, bone alkaline
phosphatase, and osteocalcin all increased significantly in the
eight treated females (Welt et al., 2004). Whereas acute eating
disorders represented an exclusion criterion in this study, it is
unknown if one or more of the eight treated females had a positive
history for an eating disorder and AN in particular.
Partially as a result of hypoleptinemia, adolescent patients
with AN show poor bone accrual followed by increased bone
loss, which can entail lifelong low bone density, degraded
bone architecture, and a higher risk of fractures (Sienkiewicz
et al., 2011; Chou and Mantzoros, 2018). Again as a proof
of principle, treatment with recombinant leptin of eleven
lean and strenuously exercising hypoleptinemic females with
hypothalamic amenorrhea over a period of nine months within a
RCT increased bone mineral content and as a trend bone mineral
density in comparison to the nine controls who received placebo
(Sienkiewicz et al., 2011).
Based on leptin’s stimulating effects on hematopoiesis (Cioffi
et al., 1996; Gainsford et al., 1996), it can be speculated that
recombinant leptin may prove beneficial in starvation-related
severe reduced blood cell production, which represents an
infrequent somatic symptom among patients with AN. In a
sample of 318 patients ascertained between 1991 and 2012, 17% of
patients had anemia, 8% neutropenia, and 9% thrombocytopenia.
These hematologic abnormalities were associated with the
duration of illness and protein energy malnutrition including
BMI (De Filippo et al., 2016). Substantially higher rates have been
observed in a more severely emaciated adult sample; weight gain,
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FIGURE 2 | Serum leptin concentrations of a patient with anorexia nervosa (Hebebrand et al., 1997). Serum leptin concentrations of a patient with anorexia nervosa
at admission for inpatient treatment, during weight gain, intermittent weight maintenance, and renewed weight loss (numbers indicate BMI in kg/m2; Hebebrand
et al., 1997). The figure is reproduced with the permission of the copyright holder (Prof. Dr. Johannes Hebebrand).
achieved via short term hospitalization, substantially reduced
the rate of neutropenia (Sabel et al., 2013). The hematologic
deficiencies observed in patients with AN have been attributed
to starvation-mediated gelatinous marrow transformation which
resolves with nutritional rehabilitation (Sabel et al., 2013). Single
case reports of patients with AN have shown that life-threatening
sepsis may ensue as a consequence of neutropenia (Foppiani
et al., 2014; Komatsu et al., 2018). In conclusion, in the proposed
future clinical trials (see below), we recommend to co-assess
hematological parameters to determine if metreleptin improves
the hematological status of patients with AN.
BEHAVIORAL AND COGNITIVE
SYMPTOMS OF ANOREXIA NERVOSA
POTENTIALLY AMENABLE TO
TREATMENT WITH METRELEPTIN
Apart from a potentially beneficial effect of metreleptin on
starvation-related somatic symptoms, we perceive the need to
assess its effects on behavior and cognition of patients with AN
in future clinical trials. We perceive severe hyperactivity as the
currently primary potential indication for treatment of patients
with AN with metreleptin; however, we subsequently also address
potentially beneficial effects on cognitions and the reward system.
Is Hyperactivity in Anorexia Nervosa
Amenable to Treatment
With Metreleptin?
Severe hyperactivity presents a substantial challenge to the
patient, caregivers, and treatment teams (Casper, 2018). In light
of rodent studies that have convincingly demonstrated that
SIH can be successfully suppressed and treated via exogenous
application of leptin, we summarize both the rodent data and the
clinical phenotype in humans including studies looking into an
association between leptin levels and physical activity levels in
patients with AN.
Activity-Based Anorexia (ABA) as a
Rodent Model for Anorexia Nervosa
Food restriction to one hour per day in rats or 2–4 h per day
in mice entails increased RWA and a decline in food intake
entailing weight loss, which can exceed 30% of baseline weight
(Hall and Hanford, 1954; Routtenberg and Kuznesof, 1967; Ross
et al., 2016). In addition to the classical model of ABA, the
initiation of a food restriction to 60% of ad libitum intake
termed semi-SIH also results in increased RWA by 300–400%
within days (Exner et al., 2000). Immediately prior to the daily
presentation of food in ABA, rodents will further increase their
activity (food-anticipatory activity). Whereas an increased level
of activity is usually compensated by an elevated energy intake,
both ABA and SIH can ensue in the death of the rodent due
to starvation (Routtenberg and Kuznesof, 1967). In contrast,
rats in cages without a running wheel survive the restricted
access to food. Accordingly, it is potentially only the combination
of timed availability/shortage of food and access to running
wheels that initiates the precipitous reduction in body weight
(Foldi et al., 2017a).
Activity-based anorexia (ABA) recapitulates many of the
pathophysiological and behavioral hallmarks of AN, including
a reduction in food intake, excessive exercise, dramatic weight
loss, loss of reproductive cycles, hypothermia, and anhedonia
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(Foldi et al., 2017a). ABA also captures the hypoleptinemia-
induced up- or downregulation of the hypothalamus-pituitary-
end organ axes entailing hypercortisolemia, reduced levels
of FSH and LH along with other endocrine alterations
including hyperghrelinemia, and physiological changes such as
hypothermia (Hebebrand et al., 2003; Ross et al., 2016). As
pointed out by Foldi et al. (2017a), the major obstacle in
relation to AN is the utilization of a model that incorporates
“voluntary” food restriction rather than imposed starvation.
Because rats in the ABA model do not eat sufficiently during
the 60–90 min ad libitum access to food to survive (in
contrast to control rats without a running wheel in their cage
subjected to the same temporal restriction of food intake), this
“voluntary” reduction in food intake may appear more similar
to the AN phenotype in humans than the SIH model with
forced energy restriction. However, the overall similarity in
symptoms between ABA and SIH suggests that this aspect is of
minor importance.
The elevated levels of physical activity have been interpreted
in evolutionary terms as “displaced food-foraging behavior”
akin to times of food shortage (Sodersten et al., 2008). An
alternative hypothesis focuses on the prevention of hypothermia
(Gutierrez and Vazquez, 2001). In the ABA model, provision
(Sherwin, 1998) of a voluntary access to a warm plate prevented
the development of hypothermia and reduced, but did not
abolish RWA (Hillebrand et al., 2005a, 2008). Accordingly,
hypothermia may increase hyperactivity, but does not solely
trigger this behavior. Nevertheless, data derived from the
ABA model have led to the proposition that increasing
ambient temperature may prove beneficial to patients with AN
(Hillebrand et al., 2005a; Carrera and Gutierrez, 2018). Further
discussion is, however, out of the scope of this review and
will be covered in another contribution to this special issue.
Interestingly, Foldi et al. (2017b) showed that an activation of
the dopamine system substantially increased food intake and
prevented weight loss in the ABA model, but left the locomotor
activity unchanged.
In light of leptin’s role in the adaptation to starvation
(Ahima and Flier, 2000b), we hypothesized that hypoleptinemia
may trigger the hyperactivity in SIH (Exner et al., 2000).
Indeed, the subcutaneous implantation of a mini-pump releasing
recombinant leptin (31 µg/day) over a period of 7 days
concomitantly to the initiation of food restriction completely
suppressed the development of hyperactivity in male rats,
whereas those treated with vehicle increased their RWA by 300–
400% (Figures 3, 4). Furthermore, implantation of the mini-
pumps 5 days after the initiation of food restriction successfully
reduced RWA to baseline values in those rats which received
leptin in contrast to those that were treated with vehicle;
suggesting for the first time that recombinant leptin can be used
to treat hyperactivity in patients with AN (Exner et al., 2000).
Surprisingly, despite the large difference in locomotor activity,
hyperactive controls did not lose more body weight during semi-
starvation for one week than leptin-treated rats, suggesting that
leptin treatment had increased the resting metabolic rate.
Hillebrand et al. (2005b) extended these findings to the ABA
model. ICV leptin treatment (4 µg/day) decreased RWA both
during the light and dark phases in female rats. Only the vehicle-
treated ABA rats developed hyperactivity and food-anticipatory
activity in the hours before feeding. Activity levels were not
influenced by leptin in ad libitum fed rats. Furthermore, food-
restricted sedentary rats did not reduce activity when treated
with leptin, indicating potential specificity of the effect of leptin
for ABA. The investigators postulated that leptin reduces the
rewarding properties of RWA (Hillebrand et al., 2005b). Leptin
treatment decreased food intake in all conditions (ad libitum–
feeding, food-restricted sedentary rats, ABA), but most strongly
in the ABA model, thus indicating that this treatment has strong
effects on food intake which override the homeostatic drive to
eat. The development of hypothermia was prevented during the
initial 4 days of the experiment in the leptin treated animals. The
effects of the reduced energy expenditure as a result of relative
hypoactivity were outweighed by leptin-induced reduced energy
intake and relative hyperthermia. After 4 days, the relative body
weight was not significantly different between leptin and vehicle
treated rats (76 and 81% of baseline body weight).
More recently, rodent studies have focused on the underlying
mechanisms and pathways. Verhagen et al. (2011) demonstrated
that acute bilateral leptin injection in the VTA decreased
RWA in a dose-dependent manner. Because the application
of the dopamine receptor antagonist flupenthixol also reduced
activity levels in the ABA model (Verhagen et al., 2009), a
leptin-induced reduction of DA tone via LEPRs in dopamine
neurons of the VTA was postulated (Hommel et al., 2006; Liu
et al., 2011). Fernandes et al. (2015) indeed found that the
DA tone in the VTA is influenced by leptin via STAT3, thus
affecting activity levels and running rewards. STAT3-knockout in
DA neurons (STAT3DAT KO) resulted in substantial increases
in both spontaneous activity and endurance running of the
respective mice. Both control and STAT3DAT KO received
either saline or recombinant leptin intra VTA prior to a
conditioned place preference task. While leptin-treated controls
showed suppressed running reward behavior, leptin had no
decreasing effect on running reward in STAT3DAT KO mice.
Since a viral-mediated restoration of STAT3 in mice reversed
the phenotype of the STAT3DAT KO and leptin showed no
effect on running reward behavior in the knockout model, leptin
seemingly inhibits running rewarding effects through STAT3 in
VTA dopamine neurons (Figure 5). Evidence was found for
dopamine-opioid interactions in the nucleus accumbens that may
contribute to heightened running reward. Because STAT3 loss of
function had little influence on the anorectic actions of leptin,
hedonic, or compulsive feeding behavior, the involvement of
STAT3 signaling in DA neurons was seemingly specific in the
control of physical activity. Thus, endurance training may be
intrinsically rewarding via moderation of LepR-STAT3 signaling
in DA neurons. The investigators speculate that the rewarding
properties of physical activity may promote the runners high,
excessive exercise and addictive like compulsive behaviors in
prone individuals. In light of the difficulties with respect to the
dissection of the cognitive and behavioral mechanisms involved
in elevated activity levels in patients with AN (Holtkamp et al.,
2006; Sternheim et al., 2015), it is worthwhile to point out that
selective deletion of the LEPR in dopamine neurons produces
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FIGURE 3 | Relative activity at different feeding states and leptin application (Exner et al., 2000). The figure is reproduced with the permission of the copyright holder
(Prof. Dr. Johannes Hebebrand).
FIGURE 4 | Mechanism and pathways linking food starvation, leptin, and physical activity according to a semi-starvation-induced hyperactivity rodent model
(adapted after Exner et al., 2000). Upper part of the figure displays the pathway of rodents exposed to food starvation with a subsequent loss in body weight due to
elevated physical activity. The lower part of the figure displays the pathway of rodents who first developed SIH and were then treated with leptin via a mini-pump.
Here, physical activity levels reached baseline physical activity level (after implementation).
anxiogenic-like behavior and increases DA activity in amygdala
(Liu et al., 2011).
Hyperactivity in Anorexia Nervosa
An elevated level of physical activity subsequently referred to
as hyperactivity or motor activation, to include mild forms, has
early on been recognized as a key symptom of patients with
AN (Bruch, 1962; Crisp, 1968; Gull, 1997); “for it seemed hardly
possible that a body so wasted could undergo the exercise which
seemed agreeable” (Gull, 1997). According to Bruch (Bruch,
1962), “overactivity is rarely spontaneously mentioned by the
patient – certainly not in long-standing cases – but it can be
recognized with great regularity if looked for. Sometimes there
has been an intensified interest in athletics and sports; more often,
these activities appear to be aimless, e.g., walking by the mile,
chinning and bending exercises, or just refusing to sit down or
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FIGURE 5 | Model for the effect of metreleptin treatment on the dopaminergic tone, physical activity and body weight.
literally running around in circles.” Bruch observed a cessation
of “overactivity,” if patients achieved an advanced degree of
emaciation. Even if the amount of exercise did not consistently
appear large to Bruch, she expressed amazement in light of
the “lacking awareness of fatigue and weakness corresponding
to the stage of malnutrition. On the contrary, the subjective
feeling is that of not being tired and of wanting to do things.”
Patients have been found to value “improving tone” as important
and health and enjoyment as less important reasons to exercise
(Keyes et al., 2015).
Motor activation includes fidgeting, frequent performance of
both isotonic and isometric (maintenance of an active posture)
muscle contractions to excessive exercise and sport activities
(Alberti et al., 2013). Whereas outpatients, for example, jog,
swim, or cycle daily for extended time periods, inpatients
may constantly walk around the ward, move their extremities
while sitting, maintain postures requiring isometric muscle
contractions, or engage in push-ups or other exercises in their
rooms, particularly when they feel unobserved. In an unspecified
fraction of patients, hyperactivity can represent a truly acute or
chronic debilitating symptom of their eating disorder.
The range of lifetime prevalence rates for “excessive physical
activity” in patients with AN varies between 38 and 80% (Davis
et al., 1997), albeit with large inter-individual qualitative and
quantitative differences (Alberti et al., 2013). In a review of
“compulsive exercise” in adolescent AN, an even wider range
between 16 and 83% was reported. Clear-cut hyperactivity (Fietz
et al., 2014) may wax and wane within an individual patient,
with the majority reporting that physical activity levels steadily
increased during the period when food intake decreased the
most (Davis et al., 1994). Because systematic medium or long-
term prospective longitudinal data are scarce – many studies
have relied on recalled data – the proportion of patients who
intermittently experience such mild or severe hyperactivity
cannot reliably be specified. According to a study that followed
up 37 adolescent patients for 1 year during treatment (Kostrzewa
et al., 2013), physical activity levels were found to decrease in
the subgroup of 11 patients with initially high levels of physical
activity and vice versa to increase in those 26 patients with
initially low physical activity, so that in the end, both subgroups
had comparable levels. Physical activity remained stable after 1
year. Recovered patients with initially high physical activity had
a significantly higher fat mass during the follow-up (Kostrzewa
et al., 2013); unfortunately, leptin levels were not measured at
admission. On a cross-sectional basis, 35% of 153 consecutively
admitted adult inpatients (mean age 26.0 ± 8 years; mean BMI
15.0 ± 1.7 kg/m2) were classified as excessive exercisers, defined
via a minimum of 1 hour of obligatory exercise performed for
at least 6 days per week in the month preceding admission
(Bewell-Weiss and Carter, 2010). Based on our own clinical
experience, we estimate that 10–15 and 30–50% of adolescent and
adult patients, respectively, are hyperactive to an extent that the
treatment team attempts to curtail this behavior.
Methodological differences in measurement, inpatient or
outpatient settings, length of observation, age, illness duration,
and mean BMI have entailed heterogeneous results. Methods
to measure physical activity have included retrospective analysis
of medical records, activity diaries, experience sampling,
questionnaires or self-ratings using visual analogue scales, expert
ratings using semi-structured interviews, clinician rated scales
of physical activity and motor restlessness, and devices such as
actometers and pedometers to measure movement (Hebebrand
et al., 2003; van Elburg et al., 2007; Gummer et al., 2015). Patients
seemingly under-report their physical activity upon comparison
with actometry-based data (Alberti et al., 2013). In an adolescent
inpatient setting, the ratings of physical activity based on visual
analogue scales filled in by two nurses were reasonably well
correlated with average actometer activity scores (r = 0.61) for the
18 patients (van Elburg et al., 2007). In contrast, the correlation
between the patients’ scores, based on the same visual analogue
scales, with the actometer data was lower (r = 0.44) and non-
significant. Not surprisingly, different investigators have used
various terms to describe the motor activation, thereby revealing
different underlying etiological concepts (Table 2), which center
on the perceived syntonicity of the behavioral activation as one
important dimension. The compulsive nature is seemingly more
relevant than the absolute amount of physical activity (Adkins
and Keel, 2005; Cook and Hausenblas, 2008). Adkins and Keel
(2005) identified at least 31 different terms for unhealthy exercise.
There is currently no international consensus as to the
operationalization of hyperactivity or motor restlessness in
patients with AN. It has been proposed to specifically
include “behavior(s) indicative of high energy expenditure”
as a facultative diagnostic symptom in classification systems
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TABLE 2 | Terms used for describing motor activation in the acute stage of
anorexia nervosa arranged according to insinuated syntonicity
(Hebebrand et al., 2003).
Ego-syntonic Activation and arousal,
paradoxical liveliness,
excessive vitality, abundance of
physical energy
Neutral Extensive exercise, intense
athleticism, hyperactivity,
over-activity, motor
restlessness, diffuse
restlessness
Ego-dystonic Excessive exercise,
exaggerated need for physical
activity, compulsive exercising
(Hebebrand and Bulik, 2011). The lack of a common standard
substantially hampers the interpretation of published data.
Hence, the split of a referred sample according to physical
activity levels (Kostrzewa et al., 2013) may well render
different associations than a comparison of severely hyperactive
with non-hyperactive patients. Exercise in the eating disorder
literature is generally characterized quantitatively in terms of
frequency, duration, and intensity and qualitatively via features
of compulsivity (Wyatt, 1997) including rigidity, increasing
priority over other activities, being rule-bound, detailed record
keeping, and feelings of guilt and anxiety over missed exercise
sessions (Adkins and Keel, 2005; Noetel et al., 2017). A third
dimension encompassing the motivation for exercise has also
been proposed (Mond et al., 2006; Boyd et al., 2007). In
patients with eating disorders, the term compensatory behavior
describes the intention to counteract weight gain associated binge
eating or to prevent weight gain (Lepage et al., 2008). Another
classification is based on (a) excessive exercise (i.e., exceeding
6 h per day) and/or evocation of negative emotional states
upon postponement of exercise, (b) high commitment to exercise
despite adverse consequences for health or social contacts, and
(c) a restlessness which entails a continuously active posture,
fidgeting, or the inability to sit still (Kostrzewa et al., 2013).
Whereas the elevated physical activity may initially be
experienced positively, it can turn into a behavior largely out of
control. Because patients can resort to physical activity/exercise
to intentionally lose weight or maintain a reduced body weight,
the distinction between purposeful/intended and compulsive
physical activity is at times fuzzy on an individual basis. Indeed,
true exercise represents an intentional, planned, structured, and
repetitive type of physical activity (Achamrah et al., 2016).
However, there is no doubt that patients can perceive the
urge to relentlessly exercise as beyond their control (see case
report, Box 1). Patients should be specifically queried as to their
perception of control of their physical activity. Their overall
lack of experienced anxiety in light of their condition including
excessive exercising may induce the observer to assume a more
ego-syntonic quality of the respective behaviors.
To provide guidance with respect to the controversy regarding
the definition of clinically significant exercise, Noetel et al. (2017)
conducted a Delphi study including 25 experts in adolescent
AN to synthesize knowledge. The preferred term for unhealthy
exercise in adolescents with AN was compulsive exercise. The
panel did not consider a uniform cut-off as helpful for the
definition of unhealthy exercise, instead the consideration of
the exercise behavior in the context of the adolescent’s overall
presentation and history was deemed relevant. A large portion of
the endorsed items for unhealthy exercise were clinical markers of
compulsivity such as distress associated with ceasing or delaying
exercise, behavioral rigidity, and exercise performed despite
negative health consequences.
From a psychopathological perspective, higher levels of
anxiety, anhedonia, depression, inner restlessness (being anxious
and jittery), irritability, somatization, obsessive thoughts,
rigidity, restraint in emotional expression, perfectionism,
high persistence, low novelty seeking, reward dependence,
greater impulse control, obsessive-compulsive personality,
and comorbid obsessive compulsive disorder have been
associated with hyperactivity in AN (Davis et al., 1999; Davis
and Woodside, 2002; Hebebrand et al., 2003; Holtkamp
et al., 2004, 2006; Pike et al., 2008; Carrera et al., 2012;
Sternheim et al., 2015; Achamrah et al., 2016). These
associations may be causally related; for instance, anxiety
may trigger hyperactivity or vice versa (Sternheim et al.,
2015; Achamrah et al., 2016). Hyperactive patients are
characterized by greater eating disorder psychopathology
including more bulimic symptoms and a greater degree of
body dissatisfaction and weight preoccupation (Hebebrand
et al., 2003). Hyperactivity has been associated with
both the restricting and binge eating/purging type of AN
(Shroff et al., 2006; Dalle Grave et al., 2008).
A logistic regression analysis based on 153 inpatients with
AN explained 31% of the variance in exercise status (excessive
vs. non-excessive). Higher levels of dietary restraint, depression,
and unexpectedly self-esteem predicted the exercise status as
did, also unexpectedly, lower levels of obsessive-compulsive
symptomatology and the restricting subtype of AN (Bewell-
Weiss and Carter, 2010). The investigators point to the
limitation that the results may have been distorted because
the patients had not been able to exercise currently. Seemingly
in contrast to the study of Bewell-Weiss and Carter (2010);
Young et al. (2013) observed a positive association between
excessive exercise and obsessive-compulsive symptoms in their
literature review.
A high level of premorbid physical activity has been found
to be associated both with AN per se and the hyperactivity
of these patients in particular (Kron et al., 1978; Davis et al.,
1994, 1997; Kostrzewa et al., 2013). According to Davis (1997),
60% of their interviewed hospitalized patients were competitive
athletes prior to the onset of AN. In addition, 60% of patients
predated sport or exercise to the onset of their eating disorder;
the authors particularly noted that the eating disorder began
after the patients had terminated participation in their sport.
On average, the patients were more physically active than co-
interviewed control subjects from early adolescence onward. This
high level of activity may be an early indicator of the illness or
alternatively and in our opinion more likely represents the upper
end of inter-individual range of physical activity prior to the onset
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BOX 1 | 28 year old female with AN since age 15 with restricting and binge-eating/purging phases, BMI upon initial episode 14 kg/m2. Contestant at the national
level for gymnastics prior to development of AN. After several treatment episodes partial stabilization for three years at BMI of ∼17.5 kg/m2.
During a trip to Africa relapse as a consequence of diarrhea and weight loss of 6 kg, development of extreme hyperactivity (walking briskly up to 10 h a day);
subsequent further severe weight loss (BMI of 10 kg/m2); admission to the intensive care unit in pre-terminal condition; severe leukopenia.
With adequate intensive care rapid improvement of the general condition (BMI 13 kg/m2), but further increase of hyperactivity. High dosages of atypical neuroleptic
medication and benzodiazepines without substantial effect on hyperactivity.
of the disorder. In a subsequent study, Davis (1997) showed that
a significantly greater proportion of those patients who reported
being highly physically active during childhood became excessive
exercisers during their eating disorder as compared with their
average/less active counterparts. Accordingly, elevated levels of
premorbid physical activity would represent a risk factor for the
development of hyperactivity upon onset of AN. In our clinical
experience, adolescents who were engaged in competitive sports
many months prior to the onset of AN frequently develop severe
hyperactivity early in the course of their eating disorder.
At an epidemiological level, high activity levels have been
linked to disordered eating behavior (Hebebrand et al., 2003).
For example, the odds of ever being diagnosed with an eating
disorder were 2.64 times higher for people who exercised more
than 5 h per week in comparison to people with lower activity
levels (Kostrzewa et al., 2013). We are unaware of a twin study
related to hyperactivity in monozygotic twins concordant for AN;
in general, the heritability estimate for physical activity levels is in
the range of 0.5–0.6 (e.g., Kostrzewa et al., 2013).
In our experience, severe hyperactivity may stand in the way
of the initiation of voluntary inpatient treatment, particularly
in adults. Even after admission, both the treatment team and
the respective patient may find it challenging to deal with
hyperactivity within the constraints of a ward, thus, at times
entailing a premature discharge. Hyperactivity has, however, also
been associated with longer hospital stays and a chronic course
(Solenberger, 2001; Achamrah et al., 2016).
Complications of excessive hyperactivity in AN include
an increased risk of overuse injuries, bone fractures, and
cardiovascular complications (Haddad et al., 1997; Dalle Grave,
2009). The prognostic significance of hyperactivity has been
judged controversially. Some investigators have found evidence
for a poor prognosis and an increased risk of relapse (Carter et al.,
2004; Dalle Grave et al., 2008; Achamrah et al., 2016); in contrast,
Kostrzewa et al. (2013) observed a better prognosis at the one year
follow-up in adolescent patients who presented with high levels of
physical activity.
In historic terms, clinicians dealing with hyperactive patients
recommended bed rest to curtail the amount of energy spent
for physical activity and to thus promote weight gain. However,
it has become more and more evident that the treatment of
patients with AN should include modules for physical activity.
All experts, who participated in the aforementioned Delphi-Study
(Noetel et al., 2017), recommended targeted interventions to
adequately address unhealthy exercise, as opposed to relying on
treatment approaches for AN in general. The potential benefits
of such treatment programs using different types of modules
have been summarized by Achamrah et al. (2016). However,
to our knowledge, RCTs for the treatment of hyperactivity
in patients with AN have not been performed. Particularly
atypical neuroleptics (Mehler-Wex et al., 2008) are prescribed
intermittently and off label to patients with severe hyperactivity.
Excessive exercise has not only been reported in patients with
AN. The respective behaviors have also been observed in patients
with Bulimia Nervosa and Eating Disorders Not Otherwise
Specified (Davis et al., 1997; Renz et al., 2017). Furthermore,
a link between exercise addiction and orthorexia nervosa has
been reported (Rudolph, 2018). Among female athletes engaged
in endurance sports, gymnastics, and ballet, a low energy intake
and menstrual dysfunction including hypothalamic amenorrhea
is rather prevalent (Misra, 2014). The highest prevalence is
seemingly observed in patients with AN (Davis et al., 1997)
despite single studies showing higher rates in patients with BN
(Renz et al., 2017). It is important to point out that hyperactivity is
not a common feature in famines nor was it common among the
male participants of the Minnesota Starvation Study. However,
some of the males reported symptoms indicative of restlessness
(see Casper, 2018). In addition, among individuals who survived
hunger episodes in World War II motor restlessness was also
reported (Hebebrand et al., 2003).
Attempts to correlate serum leptin levels with activity levels
measured via different methods in both adolescent and adult
patients have provided mixed results (Exner et al., 2000;
Holtkamp et al., 2006; Ehrlich et al., 2009; Kostrzewa et al.,
2013; Nogueira et al., 2013; Stengel et al., 2017), potentially
indicating that the threshold range for hyperactivity differs
individually. Similar to the rat model, in which rats are no
longer hyperactive prior to death due to starvation, exceedingly
low leptin concentrations in patients may also reflect a terminal
stage of the disorder, at which further weight loss would result
in death. The inborn and virtually total lack of leptin in
congenital leptin deficiency may explain why hyperactivity is not
a symptom in the respective rare autosomal recessive condition.
Accordingly, a non-linear relationship between circulating leptin
levels and hyperactivity appears plausible (Holtkamp et al.,
2006). Furthermore, hyperactivity in some patients may have
a strong volitional component as the term drive for thinness
suggests, which is not or only partially related to hypoleptinemia
(Exner et al., 2000).
ARE COGNITIONS AND MOOD IN
ANOREXIA NERVOSA AMENABLE TO
TREATMENT WITH METRELEPTIN?
In light of the proposed primary indication for treatment
of severe hyperactivity in patients with AN, we believe that
it is worthwhile to co-assess effects of metreleptin therapy
on starvation-related cognitions. We hypothesize that they
decrease upon treatment.
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Patients with AN acknowledge that they reflect on food,
eating, weight, and shape concerns for several hours a day.
Upon inpatient treatment, the percentage of time spent on
such thoughts will typically decrease; an adolescent patient may
state that 90% of her time awake is spent on such thoughts
during her first week of treatment, whereas 3 months later,
upon achievement of her target weight, this percentage has
decreased to 40%. Some patients state that these cognitions
are bothersome, other patients experience them as ego-
syntonic. During treatment, both clinicians and relatives
can usually observe an increasing loosening of this apparent
rigidity and obsession with such thoughts accompanied
by a greater openness and willingness to dwell on other
personal and emotional issues. Whereas both the therapeutic
setting and weight gain may underlie this improvement,
the realimentation process presumably plays the major role.
Because starvation induces a pre-occupation with food and
an altered eating behavior (Table 1), these cognitions should
especially be reduced by restitution of a body weight in
the healthy range. Importantly, as key endocrine signals
underlie this process, the application (or reduction) of such
hormones/neuropeptides and metreleptin in particular may
also entail a reduction of such cognitions and behaviors.
We hypothesize that specific cognitions and/or affective
symptoms associated with hyperactivity in patients with AN
also decrease, if hyperactivity in itself can successfully be treated
with metreleptin.
The potential impact of leptin on depression like behavior was
indirectly substantiated in mouse models with selective LEPR
ablation in the adult hippocampus (Guo et al., 2013). It is
thus carefully and more generally hypothesized that metreleptin
may entail positive effects in depression (Paz-Filho et al.,
2015). Irritability and a depressed mood represent common
symptoms in patients with AN. In the Minnesota Starvation
Experiment, these symptoms became more pronounced in
some men during the realimentation period (Guetzkow and
Bowman, 1946). Similarly, in patients with AN, mood may
deteriorate during the refeeding phase; some patients appear
anxious to overeat and to lose control of their eating
behavior, which may evolve into binge eating. On average,
however, mood and eating behavior clearly improve during
refeeding (Carter et al., 2004), which may in part be the
result of leptin-induced mood improvement. Accordingly, we
hypothesize that a depressed mood improves in patients
with AN who are treated with metreleptin. Mood should
thus be co-assessed.
ANOREXIA NERVOSA, LEPTIN,
AND REWARD
The striking behavior of patients with AN and their restriction
of food intake to the extent of self-starvation in particular
have prompted researchers to come up with potential
explanations, which more recently have focused on the
reward system including the underlying brain regions,
pathways, and neurotransmitter systems, among which the
DA system figures prominently. A genetic predisposition
(including female sex) along with specific temperamental and
personality features, hormonal factors, and brain maturation
processes occurring during puberty and adolescence may
result in a high vulnerability to AN, if food restriction is
initiated and pursued to an extent that starvation related
changes set in. A twin study has pointed to an altered
reward reactivity as a potential risk endophenotype for
eating disorders (Kanakam et al., 2017). Speculatively, the
predisposing genotype may render carriers to more readily get
entrapped in the cognitions and behaviors characteristic of AN,
if food restriction, subsequent weight loss, and the adaptation
to starvation are initiated in adolescence/early adulthood
irrespective of the reason/mechanism underlying the initially
reduced food intake.
Several investigators have argued that food restriction and
in due course starvation may in some way sensitize the reward
system, thus, contributing to or even representing an essential
feature for the relentless pursuit of thinness in patients with
AN (Keating, 2010). Psychological explanations include the
alleviation of anxiety and a dysphoric or anhedonic mood state
(Davis and Woodside, 2002); accordingly, the food restriction
including the sensation of hunger serves to regulate emotions.
The psychological effects of food restriction are embedded in the
profound physiological and biological alterations of initial and
later prolonged starvation, for which hypoleptinemia acts as a
crucial endocrine signal.
Patients with AN seemingly have disturbances in the
processing of naturally rewarding stimuli, importantly including
food. The processing of food reward is complex and modulated
by cognitive, emotional, and biologic factors that involve learned
behaviors and genetic predisposition (Frank, 2011). Evidence
from taste reward tasks indicates that patients do not differ from
healthy controls with respect to the hedonic properties of taste-
reward; their “liking” of foods is not altered in comparison to
controls. Instead “wanting” in patients for the preference for
stimuli such as high caloric foods may be reduced as a result of
the fear of weight gain (Keating, 2010).
All currently investigated neuropeptides and hormones
tightly linked to appetite and body weight regulation have
been found to be up- or downregulated in a manner
consistent with starvation (Stoving et al., 2001) in patients
with acute AN. Apart from the reduction of serum or
cerebrospinal leptin levels (Hebebrand et al., 1995, 1997;
Grinspoon et al., 1996; Mantzoros et al., 1997), examples
include the elevations of neuropeptide Y (Kaye et al., 1990) and
ghrelin (Ariyasu et al., 2001; Otto et al., 2001). Accordingly,
the neuroendocrine adaptation to starvation is seemingly not
impaired in patients. The respective abnormalities do not
persist upon recovery, suggesting that primary disturbances
of appetite regulation are not at the core of AN (Stoving
et al., 1999, 2001; Eddy et al., 2015); they may, however,
contribute to a vicious circle upon initiation of starvation
(Stoving et al., 1999).
We specifically postulate that the hypoleptinemia-induced
adaptation of the central nervous system contributes to the
initiation of such a vicious circle in individuals predisposed to
Frontiers in Psychology | www.frontiersin.org 13 May 2019 | Volume 10 | Article 769
fpsyg-10-00769 May 16, 2019 Time: 14:39 # 14
Hebebrand et al. Treatment of Patients With Anorexia Nervosa
develop AN. The role of leptin in the reward system has been
pointed out above including the link to the DA system. Leptin
has extra-hypothalamic effects (van der Plasse et al., 2015) in the
regulation of food intake, reversibly altering neural structure and
function, and modulating plasticity-dependent brain physiology
in response to food cues (Baicy et al., 2007; Paz-Filho, 2016).
An increase in gray matter concentration was observed in
anterior cingulate gyrus, parietal lobe, and medial cerebellum of
adults with congenital leptin deficiency, who were treated with
metreleptin for 18 months (Paz-Filho et al., 2015; Paz-Filho,
2016). The increase in the medial cerebellum was directly due
to metreleptin treatment. In functional studies performed with
patients with congenital leptin deficiency, metreleptin treatment
reduced activation of regions linked to hunger including insula,
parietal and temporal cortex, and enhanced activation of regions
linked to inhibition and satiety (prefrontal cortex), as well as the
posterior lobe of the cerebellum. Somewhat divergent from these
results, Frank et al. (2011) and Paz-Filho (2016) observed changes
in homeostatic (hypothalamus) and reward-related brain areas
[striatum, orbitofrontal cortex (OFC), substantia nigra/VTA,
amygdala] 3 days and 6 months after initiation of metreleptin
therapy in an adolescent with congenital leptin deficiency. In a
follow-up study conducted after 12 and 24 months, metreleptin
therapy was associated with activation changes in homeostatic,
hedonic, and frontal control regions (Frank et al., 2013).
In AN, it would appear likely that the detected higher
connectivity between the OFC and the hypothalamus on the left
and the lower connectivity between basolateral nucleus of the
amygdala and hypothalamus on the right (Frank et al., 2016)
represent a structural adaptation to starvation in patients with
AN. The involvement of the hypothalamus is in line with its
key role in appetite and body weight regulation (Frank et al.,
2016) and indicative of an altered connectivity which extends
beyond the reward system. With respect to this system, Frank
et al. (2016) detected a bilaterally higher connectivity between
insula, frontal cortex, and ventral striatum in eating disordered
patients. The investigators discussed that the effective network
connectivity from anterior cingulate to ventral striatum and to
the hypothalamus may provide a possible biological correlate
for the hypothesis that patients with eating disorders are able to
override homeostatic signals.
The critical role of the dorsal striatum in the establishment
and expression of action control and learned automatic behaviors
was supported in a study based on functional magnetic resonance
imaging (fMRI) to compare blood oxygen level-dependent
(BOLD) activity among women with acute AN with that of
healthy female controls upon use of a food choice task that
captures the restrictive caloric intake (Foerde et al., 2015). The
persistent, maladaptive food choice in AN is subserved by fronto-
striatal networks that are crucial for the development of habitual
behavior and maladaptive human behaviors.
Giel et al. (2013) compared the reward of physical activity
in patients with AN, athletes, and controls using eye-tracking.
Both patients and athletes rated active stimuli as more pleasant
as compared to non-athletes, and patients rated passive stimuli
as more unpleasant than both control groups. A strong
correlation between reward sensitivity and attentional orienting
was observed among the patients; furthermore, the amount
of individually performed physical activity and pleasantness
ratings of active stimuli were associated with both attentional
orienting and engagement. The negative appraisal of physical
inactivity might promote physical activity and hyperactivity
in patients with AN. In the corresponding fMRI study, both
patients with AN and athletes revealed a hyperactivation in
the somatosensory cortex in response to physical activity
stimuli, suggesting that these stimuli are perceived as more
rewarding than in non-athletic controls. Physically inactive
stimuli resulted in an increased response inhibition associated
activity in the patients with AN only, whereas physically
active stimuli resulted in a reduced activity in the cerebellum
(Kullmann et al., 2014).
Based on the concept of stress induced reward linked to
illness behaviors (Bergh and Sodersten, 1996), Keating (2010)
formulated the reward contamination theory, according to
which patients experience otherwise rewarding stimuli (e.g.,
food) as punishing, and vice versa otherwise punishing (or
aversive) stimuli (e.g., self-starvation, excessive physical activity,
emaciated body image) as rewarding. It is unclear whether
reward contamination begins as a result of an aversion to
food or increasing social/cognitive goals of thinness. The
term perverse reward has also been coined (Park et al.,
2014) to characterize the pursuit of thinness and compulsive
engagement in extreme dietary restraint, often in combination
with over exercising. Perverse reward is considered to be
accentuated in line with starvation; the clinical problems
inherent to treatment of AN are due to the compulsivity
associated with perverse reward. Because food restriction
amplifies reward processes, the self-enforced abstinence in
AN may entail that food becomes more rewarding, thereby
explaining some cognitions (e.g., constant thoughts of food)
and behaviors (e.g., ritualistic eating behavior) that apply to
both patients with AN and subjects exposed to starvation
(Park et al., 2014).
The anterior cingulate cortex, the insula, the entire
fronto-striatal neurocircuit, and the default mode network
have been proposed to represent key loci for reward-
contamination/perverse reward (Keating, 2010; Park et al.,
2014). The ventral striatum is involved in coding the pleasure
of a reward. Motivational salience, which too has been linked
to the ventral striatum, is defined as the process through which
a stimulus is converted from a neutral representation into an
attractive and wanted incentive that a person will work to acquire
(“wanting”) (Park et al., 2014). The dorsolateral prefrontal cortex
has been suggested to modulate striatal activity that underlies the
approach or avoidance of food (Kaye et al., 2009). Accordingly,
an increased activation in this area in response to aversive food
stimuli in recovered patients with AN may, therefore, represent
an enhanced attempt to minimize exposure to such stimuli (Kaye
et al., 2009; Park et al., 2014). Increased functional connectivity
between the default mode network and both the precuneus and
the dorsolateral prefrontal cortex in recovered patients suggests
that resting state networks involving self-referential processing
and cognitive control may be dysfunctional in AN (Park et al.,
2014). Park et al. (2014) conclude that “neuroimaging studies
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suggest that altered eating may be a consequence of aberrant
reward processing in the context of heightened cognitive control
processes and interoceptive deficits, leading to poor awareness of
homeostatic needs”; these mechanisms promote the compulsive
behaviors observed in patients.
Evidence implicates the DA system in the aberrant reward
processing of patients with AN (for links between the DA
system and leptin see above). Keating (2010) proposed that an
upregulation of the stress HPA and the dopamine system are
linked to the self-starvation and excessive exercise of patients
with AN, thereby entailing that the behaviors reinforce the
illness and emaciation. Whereas the upregulation of the HPA
axis represents a consequence of starvation, the persistence of
abnormalities of the DA system in recovered patients was deemed
as suggestive of a trait marker. Thus, an increased D2 and D3
receptor binding in the reward linked antero-ventral striatum was
identified in recovered patients (Kaye et al., 1999; Frank et al.,
2005). Because the binding potential of [(11)C]raclopride used to
assess dopamine D2/D3 receptor binding was positively related
to harm avoidance in the dorsal caudate and dorsal putamen,
decreased intra-synaptic dopamine concentration or increased
D2/D3 receptor density or affinity may be associated with AN
and contribute to the characteristic harm avoidance or increased
physical activity found in AN. Indeed, the finding of reduced
concentrations of dopamine metabolites in the cerebrospinal
fluid of recovered individuals relative to controls (Kaye et al.,
1999) supports this hypothesis. An altered DA activity in AN is
further suggested by the observation of an increased eye-blink
compared with controls (Barbato et al., 2006). A comparative
study based on a taste reward task in patients with AN, subjects
with obesity and controls suggested that in obesity dopamine
related pathways may be less sensitive, whereas the opposite holds
true for AN (Frank et al., 2012).
Based on an elevated prediction error signal in a sample
of patients with AN, food restriction and weight loss
were postulated to be associated with sensitization of
the dopamine system, potentially in order to stimulate
food approach. The elevated prediction error response
may reflect increased harm avoidance, because the
biological mechanism to seek food is not compatible
with the high drive for thinness and body dissatisfaction,
entailing a conflict between food approach mechanisms
and cognitive-emotional processes that oppose eating.
Prediction error activation may then become part of a
fear-driven mechanism that includes the ventral striatum
to override homeostatic signals from the hypothalamus
(Frank et al., 2018).
In conclusion, brain-imaging studies of brain reward
function in AN are strongly indicative of brain reward system
alterations. Whereas some evidence points to primary
disturbances, persistent longer term starvation-induced
effects cannot be excluded (King et al., 2018). Thus, several
rodent studies have revealed inductions of alterations of
brain reward pathways in relationship to energy intake;
in essence, food restriction sensitizes, whereas excessive
food intake desensitizes reward pathways (see Frank et al.,
2012). A psychological explanation for the development
and persistence of AN postulates that a reluctance to gain
weight may lead to an aversive appraisal of food- and taste-
related stimuli. Accordingly, cues compatible with this
aberrant mode of thinking become rewarding; attribution
of motivational salience to these cues promotes anorectic
behaviors and elicit the anorectic “habit” (O’Hara et al.,
2015). We propose that adaptation of the central nervous
system to starvation (crucially initiated via hypoleptinemia)
in itself may represent a strong determinant for the anorectic
“habit” (Figure 6). Both the psychological (O’Hara et al., 2015)
and the endocrine induced starvation hypotheses focus
on the reward system and postulate an overlap between
AN and addiction.
FIGURE 6 | Model for the entrapment of patients with anorexia nervosa due to an addictive like state of starvation, which evolves after initial food restriction and
entails an internal reinforcement.
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THE NEED FOR CLINICAL TRIALS
We have perceived the need for the initiation of clinical trials
to assess the potential merits of metreleptin in the treatment
of patients with AN for several years (Exner et al., 2000;
Hebebrand and Albayrak, 2012). However, our past contacts with
representatives of the companies with the rights on metreleptin
proved unsuccessful with respect to the initiation of a clinical
trial. The elucidation of the central pathways operative in
appetite and body weight regulation has enabled the evaluation
of potential novel treatments of AN. Recently, promising results
were achieved in a 4 week long RCT encompassing 22 patients
with AN with the ghrelin agonist relamorelin, which led to a
shorter gastric emptying time and a trend toward greater weight
gain (Fazeli et al., 2018). The fact that three patients stopped
the use of relamorelin due to increased feelings of hunger,
underscores problems inherent to the use of an orexigenic agent
to treat this eating disorder.
The recent FDA (Meehan et al., 2016) and EMA (EMA,
2018) approvals of metreleptin for the treatment of lipodystrophy
render the initiation of trials into other hypoleptinemic disorders
possible with AN ranking prominently among these. Instead of
increasing the already elevated orexigenic drive, recombinant
leptin could ameliorate the starvation-related symptomatology
(Table 1) in patients in light of its key role in the endocrine-
induced adaptation of the organism to starvation. Thus,
treatment could entail a (partial) resolution of secondary
symptoms of this eating disorder leading to a “residual”
symptomatology with an ensuing preponderance of the primary
cognitions and, thus, a (partial) clinical dissection of the
intertwined primary and starvation-related symptoms of AN
(Hebebrand and Bulik, 2011). In weight restored patients,
metreleptin therapy may also speed up the recovery of the
reproductive axis with potentially beneficial effects on bone
health. Initially, we suggest to focus on severe AN associated
hyperactivity (Table 3). Such a trial would allow the assessment
of other potentially beneficial effects on the psychopathology of
these patients among which we particularly suggest that food
related cognitions would decrease during therapy.
In more general terms, metreleptin may reduce the reward
inherent to the process of the endocrine initiation of starvation in
thus predisposed subjects. The process of starvation is somehow
intricately linked to AN (Steinglass and Foerde, 2018), thus,
driving patients to “perversely” (or paradoxically) pursue the
restricted energy intake. We hypothesize that the obsessive and
perverse urge to continue to maintain (or even increase) the
reduced energy intake may represent an addiction like state
(Figure 5). If this hypothesis is correct, a patient who is in
the initial stages of AN may profit from early treatment with
metreleptin. The induced halt and reversal of the endocrine
adaptation to starvation would accordingly neutralize the
addictive state so that patients no longer experience reward via
a continued reduction of energy intake. In patients with longer
standing AN, metreleptin may also help to reduce the reward
associated with starvation, thus alleviating the entrapment in the
disorder. The mere reduction of the obsessive thoughts of food
could in theory entail that the patient no longer perceives her
restricted food intake as a major accomplishment in the sense that
is worthwhile to fully engage in.
POTENTIAL SIDE EFFECTS AND RISKS
OF TREATMENT WITH
RECOMBINANT LEPTIN
As with any other treatment, potential side effects warrant a
crucial reflection (Table 4; a complete overview is beyond the
scope of this review). Treatment with metreleptin can provoke
TABLE 3 | Potential indications for clinical trials to assess the effects of metreleptin therapy for patients with anorexia nervosa (AN).
Primary outcome Remarks
Physical activity level A priori highest probability of efficacy; inclusion of not severely emaciated patients ≥18
years, who can provide informed consent. Co-assessment of inner restlessness,
anxiety, and obsessive thoughts related to exercise outcomes (see first column).
Co-assessment of other psychopathological features (e.g., other eating disorder
specific cognitions) and multiple safety parameters. Clear a priori determination of
dosage increments, maximal dose and lengths of treatment for both unsuccessful and
successful treatment. A priori definition of successful treatment. Precautions and close
monitoring required to avoid metreleptin-induced weight loss
Self- (and clinician-)rated quantity (e.g., percent of time) of (a)
starvation-related cognitions including food and eating and body
weight-related ruminations, (b) abnormal eating behaviors, (c)
mood/anxiety/obsessions and compulsions, and (d) reward
sensitivity
Initial evidence for an effect on such cognitions/behaviors/mood to be obtained in trials
for hyperactivity; co-assessment of multiple safety parameters. Initial inclusion of adult
patients only, patients <18 years can be included, if treatment-related serious adverse
events do not occur (patient/parental consent required)
BMI at end of study to assess halt of progression of early stage AN Patients of any age whose initial weight loss began less than ≤4 months ago
a) BMI at end of study to assess effectiveness in relapse prevention
b) Weeks until first relapse
Patients of any age who initially recovered from first episode of weight loss and have
maintained their target weight for at least 2 months with subsequent loss of 2 kg as an
indicator for a relapse Patients of any age who have achieved their target weight
Menarche or resumption of menses Patients aged ≥14 years who have maintained their target weight for 6 months;
requirement of a relative fat mass within the normal range
Bone density Treatment of adult patients with osteoporosis and/or fractures
The rank order provides guidance as to the temporal enrollment of the respective trials.
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TABLE 4 | Risks and adverse reactions to metreleptin (results from two studies among women with hypothalamic amenorrhea and package insert information of
Myalept R© for the United States, Myalepta for the European Union). This information is supplied without liability.
Welt et al., 2004× “There appeared to be no adverse effects (including injection-site reactions) during therapy with
r-metHuLeptin. Subjects reported a qualitative decrease in appetite, primarily during the third
month, but otherwise felt well”
Chou et al., 2011 ; Sienkiewicz et al., 2011 Withdrawals n = 2 (injection site reaction and weight loss)
Mild injection site reactions n = 2
Non-neutralizing antileptin antibodies
No other clinically adverse events
Myalept R© Package insert
Risks+ Development of antibodies that neutralize endogenous leptin and/or MYALEPT
Lymphoma
Hypoglycemia with concomitant use with insulin and insulin secretagogues
Autoimmunity
Hypersensitivity
Benzyl alcohol toxicity
Adverse reactions∗ (N = 48) Headache, hypoglycemia, decreased weight each N = 6
Abdominal pain each N = 5
Arthralgia, dizziness, ear infection, fatigue,
nausea, ovarian cyst, upper respiratory tract
infection
each N = 4
Anemia, back pain, diarrhea, paresthesia,
proteinuria, pyrexia
each N = 3
× Incidence in female study participants (n = 8) with hypothalamic amenorrhea (Welt et al., 2004). Incidence in female study participants (n = 11) with hypothalamic
amenorrhea (Chou et al., 2011; Sienkiewicz et al., 2011). +As stated in the Instructions for Use, Manufactured for: Aegerion Pharmaceuticals, Inc. Cambridge, MA 02142
MYALEPT is a registered trademark of Aegerion Pharmaceuticals, Inc. PN 4086-00 Issued August 2015 MYA/US/058 10/15. ∗ Incidence in patients with generalized
lipodystrophy receiving MYALEPT in an open-label, single-arm study.
the occurrence of several adverse events. The most frequent
adverse events are development of anti-metreleptin antibodies,
headache, nausea, hypoglycemia, decreased weight, and increased
risk of infections (Ajluni et al., 2016; Brown et al., 2018). Table 4
lists the risks and side effects of the MYALEPT R© information
package to be used upon metreleptin treatment. However,
additional adverse events such as urinary tract infection (Ajluni
et al., 2016) and hair loss (Chan et al., 2011) have been reported.
The potential weight loss due to metreleptin therapy in patients
with AN would warrant special attention and consideration in
clinical trials. Among women with hypothalamic amenorrhea
(mean BMI 20.5± 2.0 kg/m2 at baseline) under leptin treatment,
body weight, and body fat decreased, especially during month 3
with higher dosages of leptin (body weight: baseline: 54.7± 4.5 kg,
month 1: 54.1 ± 4.3 kg, month 2: 54.0 ± 3.6 kg, month 3:
52.2± 3.5 kg). No adverse reactions due to metreleptin treatment
were observed (Welt et al., 2004). In another study among women
with hypothalamic amenorrhea, one out of 11 participants stopped
treatment due to persistent weight loss during the first phase,
while a second participant withdraw during the second phase.
Apart from three participants with injection site reactions, no
other adverse events due to the metreleptin treatment were seen
(Chou et al., 2011; Sienkiewicz et al., 2011).
The partial metreleptin-induced resolution of the adaptation
to starvation should entail an increased sympathomimetic and
a reduced parasympathetic tone. As such, body temperature,
heart rate, and blood pressure would likely increase in organisms
weakened by starvation, thus, necessitating a close monitoring.
Obviously, these alterations would entail an elevated resting
energy expenditure, which might need to be compensated via
an increased energy intake. The initiation of treatment with
metreleptin would appear grossly negligent if the patient a priori
does not agree to increase his/her energy intake accordingly. The
overall goal of weight restoration resulting in the synthesis of a
sufficient amount of endogenous leptin must be maintained, thus
entailing that metreleptin is an intermittent therapy only.
Because many patients with AN may no longer perceive
hunger, the elevated leptin signal should not entail a reduced
appetite, and, as a consequence an even further reduced
energy intake. If on the other hand, the patient experiences
hunger, the loss of this sensation via leptin treatment may
speculatively entail that the patient no longer is motivated
by her ability to overcome hunger; the strong incentive to
continue to stick to a reduced energy intake may no longer
be operative. Irrespective of these considerations, we again
stress the need to monitor energy intake during treatment with
human recombinant leptin to ensure that the treatment does not
entail weight loss.
Temporal aspects merit consideration. Whereas the treatment
of rats after 5 days of food restriction in the SIH model entails
a rapid and pronounced reduction of RWA (Exner et al.,
2000), the hypothesized effect on AN related hyperactivity may
require more time in humans. Obviously, the treatment goal of
restoration of menstruation may require several months for the
reproductive axis to recover, even if leptin serum concentrations
are boosted to the normal range via application of metreleptin.
All endocrine/physiological barriers to resumption need to be
overcome including for instance the renewed growth of the
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ovaries. In this context, it deserves to be pointed out that among
leptin deficient individuals, who harbor relevant mutations in
the leptin gene, antibody production against leptin has been
observed. As a rule, a transient halt in treatment enabled renewed
and effective treatment with recombinant leptin (Farooqi et al.,
2002; Frank et al., 2013); to our knowledge, no serious side effects
have been observed in patients with inborn leptin deficiency
despite treatment lasting for several years.
CONCLUSION
In the light of the problems patients and their families, friends,
and partners struggle with, physicians and the pharmaceutical
industry have the obligation to test novel treatments for AN.
Rodent data and more importantly, successful small scaled trials
for both hypothalamic amenorrhea and osteoporosis (Welt et al.,
2004; Sienkiewicz et al., 2011) in young and lean females suggest
that the risks inherent to treatment with leptin are manageable,
if adequate safety precautions are met. Metreleptin might prove
to be effective in treating several starvation induced symptoms of
AN including hyperactivity, eating disorder-related ruminations,
and in addition impairments in bone metabolism, reproductive
function, and hematopoiesis. Finally, if the adaptation to
starvation is rewarding or even addictive, patients may be able
to more readily overcome their eating disorder. If metreleptin
proves successful in the management of patients with AN,
psychotherapy and other treatment modalities will benefit from
an incorporation of the respective findings. Importantly, it
remains to be seen what percentage of patients would be willing
to be treated with metreleptin (Hebebrand et al., 2019, in press).
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